Heart Failure
Conditions
Interventions
Group 1:Therapy by ultrafiltration device FQ-16
Group 2:addition of new diuretics to the original dose of loop diuretics V2 receptor blocker(tolvaptan)
Sponsors
Shanghai Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) Patients admitted to hospital due to acute heart failure and acute exacerbation of chronic heart failure; (2) Patients with mild to moderate renal insufficiency (mild renal insufficiency: eGFR 60-90mL/min/1.73m2, moderate renal insufficiency: eGFR 30-60mL/min/1.73m2); (3) Diuretic resistance occurs after intravenous loop diuretic treatment: the daily treatment requirement of diuretics is furosemide>80mg, torasemide>40mg or bumetanide>2mg, the patient's clinical heart failure symptoms are still Can not completely relieve or recurrent attacks.
Exclusion criteria
Exclusion criteria: (1) Under 18 years of age; (2) GUSTO graded high risk of bleeding; (3) Complicated congenital heart disease; (4) Long-term oral warfarin after mechanical valve replacement; (5) Unable to cooperate and provide Informed consent; (6) Non-cardiac end-stage disease with an estimated survival period of no more than 12 months or the presence of other diseases (such as malignant tumors, liver cirrhosis, etc.); (7) pregnancy or planned pregnancy; (8) 12 months Orthotopic heart transplantation or installation of ventricular assist devices; (9) Cannot proceed according to the research plan or have been enrolled in the group or planned to be enrolled in other research projects or do not agree to participate in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight change;Dyspnea score; | — |
Countries
China
Contacts
Public ContactMin Zhang
Shanghai Chest Hospital
Outcome results
None listed